Deanne Lathers

1.5k total citations
46 papers, 1.1k citations indexed

About

Deanne Lathers is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Deanne Lathers has authored 46 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 20 papers in Immunology and 14 papers in Molecular Biology. Recurrent topics in Deanne Lathers's work include Immunotherapy and Immune Responses (15 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Immune Cell Function and Interaction (8 papers). Deanne Lathers is often cited by papers focused on Immunotherapy and Immune Responses (15 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Immune Cell Function and Interaction (8 papers). Deanne Lathers collaborates with scholars based in United States, Spain and Australia. Deanne Lathers's co-authors include Matthew R. Young, Nicholas J. Achille, Joseph I. Clark, Guy J. Petruzzelli, Rodney J. Schlosser, Mark A. Wright, M. Rita I. Young, Jennifer K. Mulligan, Anthony Sparano and R. M. Mulligan and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Deanne Lathers

46 papers receiving 1.1k citations

Peers

Deanne Lathers

IMMUN

ONCOL

OTORH

PHYSI

Bernard Gregory United Kingdom

Danielle M. Clancy Ireland

Chih‐Hung Shu Taiwan

Uk Yeol Moon South Korea

Caroline Diveu France

Huiqi Pan United States

Hirokazu Kurata Japan

Makoto Kurose Japan

Laura Vian Italy

Bernard Gregory United Kingdom

Deanne Lathers

561 ×0.9

IMMUN

182 ×0.3

ONCOL

375 ×1.8

18 ×0.1

OTORH

222 ×1.8

PHYSI

Citations per year, relative to Deanne Lathers Deanne Lathers (= 1×) peers Bernard Gregory

Countries citing papers authored by Deanne Lathers

Since Specialization

Citations

This map shows the geographic impact of Deanne Lathers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deanne Lathers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deanne Lathers more than expected).

Fields of papers citing papers by Deanne Lathers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deanne Lathers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deanne Lathers. The network helps show where Deanne Lathers may publish in the future.

Co-authorship network of co-authors of Deanne Lathers

This figure shows the co-authorship network connecting the top 25 collaborators of Deanne Lathers. A scholar is included among the top collaborators of Deanne Lathers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deanne Lathers. Deanne Lathers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Khushalani, Nikhil I., Patrick A. Ott, Robert L. Ferris, et al.. (2024). Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 12(3). e007364–e007364. 18 indexed citations

Sharma, Manish, Deanne Lathers, Melissa M. Johnson, et al.. (2022). 772 A phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01). Regular and Young Investigator Award Abstracts. A803–A803. 5 indexed citations

Gutierrez, Martin, Víctor Moreno, Kimberley M. Heinhuis, et al.. (2020). OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors. Clinical Cancer Research. 27(2). 460–472. 58 indexed citations

Chu, Quincy S., Ben Markman, Natasha B. Leighl, et al.. (2016). A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy. Annals of Oncology. 27. vi494–vi494. 3 indexed citations

Clark, Joseph I., Craig C. Hofmeister, John D. Norton, et al.. (2009). Phase I Adjuvant Radiation With Docetaxel in High-Risk Head and Neck Cancer. American Journal of Clinical Oncology. 32(4). 396–400. 3 indexed citations

Wise, Sarah K., et al.. (2009). Local production of antigen‐specific IgE in different anatomic subsites of allergic fungal rhinosinusitis patients. Otolaryngology. 141(1). 97–103. 28 indexed citations

Thiers, B.H., et al.. (2008). Chemokine receptor expression in non‐melanoma skin cancer. Journal of Cutaneous Pathology. 35(7). 623–629. 13 indexed citations

Gillespie, M. Boyd, Fu‐Shing Lee, Lynn Poole, et al.. (2007). Head and Neck Cancer Recurrence and Mortality in Nonselective Cyclooxygenase Inhibitor Users. Archives of Otolaryngology - Head and Neck Surgery. 133(1). 28–28. 11 indexed citations

Walsh, Jarrett, Deanne Lathers, C. Angela, et al.. (2007). Mechanisms of Tumor Growth and Metastasis in Head and Neck Squamous Cell Carcinoma. Current Treatment Options in Oncology. 8(3). 227–238. 24 indexed citations

10.

Young, Matthew R., Brad W. Neville, C. Angela, et al.. (2007). Autocrine motility-stimulatory pathways of oral premalignant lesion cells. Clinical & Experimental Metastasis. 24(2). 131–139. 8 indexed citations

11.

Day, Terry A., et al.. (2005). Melanoma of the head and neck. Current Treatment Options in Oncology. 6(1). 19–30. 10 indexed citations

12.

Rashid, Rashid M., Nicholas J. Achille, John M. Lee, Deanne Lathers, & Matthew R. Young. (2005). Decreased T-Cell Proliferation and Skewed Immune Responses in LLC-Bearing Mice. Journal of Environmental Pathology Toxicology and Oncology. 24(3). 175–192. 9 indexed citations

13.

Lathers, Deanne. (2004). Increased aberrance of cytokine expression in plasma of patients with more advanced squamous cell carcinoma of the head and neck. Cytokine. 25(5). 220–228. 86 indexed citations

14.

Lathers, Deanne, Nicholas J. Achille, & Matthew R. Young. (2003). Dendritic Cell Development from Mobilized Peripheral Blood CD34+ Cells. Humana Press eBooks. 215. 409–416. 2 indexed citations

15.

Young, M. Rita I., et al.. (2001). Impact of aging on immune modulation by tumor. Cancer Immunology Immunotherapy. 50(6). 315–320. 10 indexed citations

16.

Young, Matthew R., et al.. (2001). Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34+ progenitor cells. Human Immunology. 62(4). 332–341. 59 indexed citations

17.

Young, M. Rita I., Mark A. Wright, Deanne Lathers, & Kelly N. Messingham. (1999). Increased resistance to apoptosis by bone marrow CD34+ progenitor cells from tumor-bearing mice. International Journal of Cancer. 82(4). 609–615. 6 indexed citations

18.

Young, Matthew R. & Deanne Lathers. (1999). Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. International Journal of Immunopharmacology. 21(4). 241–252. 76 indexed citations

19.

Lathers, Deanne, et al.. (1999). Cultures derived from peripheral blood CD34+ progenitor cells of head and neck cancer patients and from cord blood are functionally different. Human Immunology. 60(12). 1207–1215. 9 indexed citations

20.

Lathers, Deanne, et al.. (1998). Inductive Sites for Rat Tear IgA Antibody Responses. Advances in experimental medicine and biology. 438. 551–556. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact